Diabetes News You Can Use
Poor diabetes management may increase dementia risk
A study in Alzheimer’s & Dementia found that type 2 diabetes alone did not raise the risk of cognitive impairment or affect the progression of cognitive impairment to full dementia. However, older adults with poorly controlled diabetes had a twofold greater risk of developing preclinical dementia than those without diabetes, and those who already had cognitive impairment with poorly controlled diabetes had a threefold greater risk of developing full dementia.
Full Story: McKnight’s Long-Term Care News (10/12)
New FDA guidelines aim to reduce US salt intake
The FDA has released new guidelines asking chain restaurants, food manufacturers and foodservice operators to voluntarily reduce sodium levels in 163 categories of the most-consumed processed, packaged and prepared foods. The move is to help reduce average American sodium intake by 12% over the next two and a half years, as well as reduce the rate of heart disease in the country, said Acting FDA Commissioner Dr. Janet Woodcock.
USPSTF updates guidance on aspirin use for CVD health
The US Preventive Services Task Force released draft guidance noting that the risks of low-dose daily aspirin to prevent a first heart attack or stroke among adults ages 60 and older outweigh the benefits, given the risk of internal bleeding associated with regular aspirin use. All adults, regardless of age, should consult with their doctor about whether to stop or start taking aspirin, task force member Dr. John Wong said.
Full Story: Reuters(10/12), The Associated Press (10/12)
Lower hypoglycemia risk found for weekly basal insulin
A midstage study presented at a meeting of the European Association for the Study of Diabetes found lower rates of overall hypoglycemia and night-time hypoglycemia among patients with long-standing type 2 diabetes who were treated with a novel once-weekly basal insulin compared with insulin degludec. The weekly insulin “achieved similar glycemic control with respect to [A1C] after 32 weeks of treatment compared to insulin degludec, despite higher fasting glucose targets in patients with type 2 diabetes previously treated with basal insulin,” researcher Juan Pablo Frias said.
Full Story: Healio (free registration)/Endocrine Today (10/12)
CDC director appeals to public to get flu vaccines
A National Foundation for Infectious Diseases poll found that 61% of more than 1,110 people said a flu shot was the best protection against influenza, although 44% of respondents said they were undecided about getting a flu shot or did not plan to do so. CDC Director Rochelle Walensky urged Americans to get vaccinated against the flu, noting that outbreaks will add to the strain on hospitals and health care professionals during the COVID-19 pandemic.
Full Story: The New York Times (10/7)
Novel biomarkers for HF hospitalization risk in T2D
A 6,106-person study published in the journal Diabetes Care found that NT-proBNP and high-sensitivity troponin T strongly predict the odds for hospitalization due to heart failure among patients with type 2 diabetes. Measuring these two blood biomarkers to gauge an individual’s TIMI Biomarker Score for Heart Failure in Diabetes can help “inform when it is a priority to treat a patient with an [sodium-glucose transport protein 2] inhibitor,” researcher David Berg said.
Full Story: Healio (free registration)/Endocrine Today (10/11)
Cell therapy cuts major amputation risk in diabetes
A study presented at the European Association for the Study of Diabetes annual meeting found that patients with diabetes who have critical limb-threatening ischemia had significantly lower risk for major amputation at five years after receiving a bone marrow-derived autologous cell therapy, compared with conservative therapy. The findings, based on data from 130 patients, also showed that both bone marrow-derived autologous cell therapy and repeated percutaneous angioplasty were associated with significantly longer amputation-free survival, compared with conservative therapy.
Full Story: Medscape (free registration) (10/5)
Empagliflozin benefits HF patients with and without T2D
Results of the EMPEROR-Preserved study showed that empagliflozin decreased heart failure hospitalization risk at similar rates among patients who had type 2 diabetes and those who did not. The 5,988-person study, presented at the European Association for the Study of Diabetes annual meeting, also showed that the drug delayed the need to start insulin in people who had prediabetes or diabetes.
Full Story: Healio (free registration)/Endocrine Today (10/4)
Men have higher mortality risks from bariatric surgery
Men who had weight loss surgery had a fivefold higher risk of death within 30 days, compared with women, possibly linked to age and overall health, researchers reported at the European Association for the Study of Diabetes conference. Men also had higher mortality risks than women on the day of the bariatric surgery and over a mean 5.4-year follow-up period.
Full Story: MedPage Today (free registration) (9/30)
Study finds racial gap in COVID-19 deaths, other causes
An analysis of death certificate data from the Census Bureau and the CDC from March to December 2020 showed Blacks, Native Americans and Latinos had higher risk of dying from COVID-19 and other causes compared with whites and Asians last year. The study, published in the Annals of Internal Medicine, found there were 477,200 excess deaths during the period, and 74% were attributed to COVID-19.
Full Story: CNN (10/4)
Diabetes Research Center
Related News
Rebecca Hull Speaker at Virtual Seminar Series
Rebecca Hull, Director of the Cellular and Molecular Imaging Core of the DRC, will be speaking the National DRC Virtual Seminar Series on October 13th at 11am PST. Dr. Hull's talk is titled “Impact of Exocrine Pancreas Pathology on Islet Function and Survival”. More event details and the link for event registration can be found in this flyer. Postdoctoral fellows and students are encouraged to sign up for the post seminar discussion.
New Findings from The Restoring Insulin Secretion (RISE) Study
The RISE Consortium continues to publish its findings from three parallel protocols in adults and youth with impaired glucose tolerance or recently diagnosed type 2 diabetes. The Diabetes Research Center played an important role in helping recruit for this seven center study. Three manuscripts were recently published in Diabetes Care on baseline predictors of worsening glycemia and alpha-cell function at baseline and in response to the interventions, the latter highlighting the impact of weight loss on glucagon responses. These three manuscripts and an editorial appear as an online compendium.
Jonathan Himmelfarb Wins Prize for Artificial Kidney Prototype
Diabetes Research Center affiliate and co-director of the Center for Dialysis Innovation (CDI) Jonathan Himmelfarb won a prize for a backpack-size kidney-dialysis device. The award was announced by KidneyX, a partner with the American Society of Nephrology and U.S. Department of Health and Human Services. This is the third prize the CDI has won with KidneyX and another phase of competition will occur next year with the goal of integrating systems to create an artificial kidney.
Michael Schwartz Selected for 2022 Endocrine Society Award
Diabetes Research Center affiliate Michael Schwartz has been selected by the Endocrine Society to receive the Roy O. Greep Award for Outstanding Research for his contributions to our understanding of the central actions of peptides on energy balance and glucose metabolism. The award will be presented at the Society’s annual meeting ENDO 2022 when he will also give a lecture on his work and other 2022 Laureate Award Recipients will be recognized.
New Core Service!
The Cellular and Molecular Imaging Core offers cost effective, rapid and user friendly options for Confocal and Super-Resolution Microscopy. Contact CMIC directors/staff for details.
